Thank you for the very good news. I am very much concerned that we have made an enormous mistake from the beginning. Comparing the two methods, it is strange to see that ECMO has become the standard of care for people who need more than a ventilator, when the cost of HBO per patient could be as low as 1% of the cost of ECMO, with even higher oxygen concentration in the blood; no trauma; no chemical anticoagulants; very low risk; probable efficacy against long Covid; and, easily usable at any stage of the disease. It would be good to point out if the reason for stopping this trial was because it would be unethical to withhold the good treatment from the control group. And if the only reason why the 3:1 improvement in this trial was not "statistically significant" was because the trial was too small to enable good reliance on the standard statistical methods.